Low Blood Pressure News and Research

RSS

Hypotension is low blood pressure. Blood pressure is the force of blood pushing against the walls of the arteries as the heart pumps out blood. Blood pressure is measured as systolic and diastolic pressures. Systolic blood pressure is the pressure when the heart beats while pumping blood. Diastolic blood pressure is the pressure when the heart is at rest between beats. You will most often see blood pressure numbers written with the systolic number above or before the diastolic, such as 120/80 mmHg. (The mmHg is millimeters of mercury-the units used to measure blood pressure.) Normal blood pressure in adults is lower than 120/80 mmHg. Hypotension is blood pressure that's lower than 90/60 mmHg.

RPCI research finds patients with metastatic kidney cancer benefit from HDIL-2 immunotherapy

A retrospective study published online ahead of print in the medical journal Urology by a physician team from Roswell Park Cancer Institute (RPCI) found that patients with metastatic kidney cancer — even those with chronic renal insufficiency — can tolerate and benefit from a treatment called high-dose interleukin-2 (HDIL-2) immunotherapy.

7 May 2014

Phosphate linked to cause high blood pressure and heart disease

Researchers find link between phosphate rich foods and an enzyme linked to cardiovascular disease. The findings also link phosphates to renal disease.

6 May 2014

FDA expands age indication of Adacel vaccine for immunization against tetanus, diphtheria, pertussis

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration (FDA) has expanded the approved age indication of Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed; Tdap) for active booster immunization for the prevention of tetanus, diphtheria, and pertussis as a single dose in persons 10 through 64 years of age.

2 Apr 2014

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Today Biogen Idec announced that the U.S. Food and Drug Administration has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body.

29 Mar 2014

FDA approves Xolair for treatment of chronic idiopathic urticaria

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives.

24 Mar 2014

Researchers develop therapy to attack cervical cancer tumors

One of the most promising technologies for the treatment of various cancers is nanotechnology, creating drugs that directly attack the cancer cells without damaging other tissues' development.

17 Mar 2014

Cell therapy: A powerful treatment for cancer patients

Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells.

24 Feb 2014

Medications to lower blood pressure after stroke does not reduce likelihood of death

A major study has found that giving stroke patients medications to lower their blood pressure during the first 48 hours after a stroke does not reduce the likelihood of death or major disability.

20 Feb 2014

Researchers shed new light on pain associated with bacterial infections

Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them.

11 Feb 2014

KKH doctors develop novel DIVA System for blood pressure management

New trial results1 have shown that the world's first Double Intravenous Vasopressor Automated (DIVA) System affords superior control of maternal blood pressure in women undergoing caesarean section under spinal anaesthesia, when compared with manually-administered medication to manage reduced blood pressure (vasopressor).

10 Feb 2014

Protein responsible for excretion of copper in body cells utilizes unique transport mechanism

We are fundamentally dependent on the presence of copper in the cells of the body. Copper is actually part of the body's energy conversion and protective mechanisms against oxygen radicals, as well as part of the immune system, and it also has great importance for the formation of e.g. hormones and neurotransmitters.

28 Dec 2013

Researchers develop new vaccine that protects against lethal pneumonia caused by staph bacteria

University of Iowa researchers have developed a new vaccine that protects against lethal pneumonia caused by Staphylococcus aureus (staph) bacteria, including drug-resistant strains like MRSA.

23 Dec 2013

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes.

16 Dec 2013

Inflating balloon inside artery after stent placement increases patients' risk of serious complications

Johns Hopkins surgeons say skipping one commonly taken step during a routine procedure to insert a wire mesh stent into a partially blocked carotid artery appears to prevent patients from developing dangerously low blood pressure, an extremely slow heart rate or even a stroke or heart attack.

12 Dec 2013

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients with blood disorders for whom standard treatments have been unsuccessful, according to data showcased today during the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans.

9 Dec 2013

NeutroPhase irrigation therapy and NPWT help treat severe flesh eating and wound infections

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced the publication of a scientific paper by Dr. John R. Crew of Seton Medical Center, Daly City, California, describing the first use of adjunctive NeutroPhase irrigation therapy in conjunction with Negative Pressure Wound Therapy to successfully manage the severely-infected wound in the arm of a patient with life-threatening 'flesh-eating' disease.

20 Nov 2013

NSU researchers selected to participate in DoD Gulf War Illness Research Program Consortium

Nova Southeastern University President and CEO George L. Hanbury II, Ph.D., recently announced that a NSU research team led by Mariana Morris, Ph.D., and Nancy Klimas, M.D., was selected by the U.S. Department of Defense as one of two DoD Gulf War Illness Research Program Consortium awardees.

20 Nov 2013

Severe sepsis mortality rates decrease over the past 20 years

A recent study from Boston University School of Medicine and Boston Medical Center shows a significant decrease in severe sepsis mortality rates over the past 20 years. Looking at data from patients with severe sepsis enrolled in clinical trials, researchers found that in-hospital mortality rates decreased from 47 percent between 1991 and 1995 to 29 percent between 2006 and 2009, a time period when no new pharmacological treatments were developed for severe sepsis.

14 Nov 2013

Calcium-channel blocker and antibiotic intake linked with small but greater risk of kidney injury

Among older adults taking a calcium-channel blocker, simultaneous use of the antibiotic clarithromycin, compared with azithromycin, was associated with a small but statistically significant greater 30-day risk of hospitalization with acute kidney injury, according to a study published by JAMA. The study is being published early online to coincide with its presentation at the American Society of Nephrology's Kidney Week 2013.

12 Nov 2013

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted and filed the company's supplemental Biologics License Application for subcutaneous use of Xolair (omalizumab) in people with Chronic Idiopathic Urticaria who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses.

11 Oct 2013